Suzhou Ribo Life Science
6938 · HKEX
Public Market Listing
Live quotes, historical charts, and market capitalization for Suzhou Ribo Life Science are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(3 total)
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
October 2027 (1)
Financial reports
Quarterly & interim (1)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | $14M | — | — | $13M | report ↗ |
Annual history (2 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $20M | $39M | — | — | report ↗ |
Suzhou Ribo Life Science reported revenue of $19.76M, up 197500.0% YoY and R&D spend of $38.97M, down 12.6% YoY for fiscal year 2024.
Figures only: this period's report disclosed no narrative text
View 1 more year
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2023-FY | <$0.1M | $45M | — | — | report ↗ |